HC Wainwright Comments on Altimmune FY2029 Earnings

Altimmune, Inc. (NASDAQ:ALT) – Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for Altimmune in a research note issued on Wednesday, January 22nd. HC Wainwright analyst P. Trucchio expects that the company will earn $1.30 per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

A number of other equities analysts have also weighed in on ALT. Stifel Nicolaus started coverage on shares of Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price objective for the company. UBS Group began coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Altimmune currently has an average rating of “Buy” and an average target price of $20.83.

Altimmune Stock Performance

NASDAQ:ALT opened at $6.93 on Monday. The firm has a market cap of $492.86 million, a P/E ratio of -4.47 and a beta of 0.22. Altimmune has a fifty-two week low of $5.28 and a fifty-two week high of $14.84. The firm has a 50-day simple moving average of $7.87 and a two-hundred day simple moving average of $7.19.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million during the quarter. During the same period in the prior year, the business posted ($0.39) EPS.

Hedge Funds Weigh In On Altimmune

A number of institutional investors have recently bought and sold shares of ALT. Geode Capital Management LLC increased its stake in shares of Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock worth $10,244,000 after purchasing an additional 74,194 shares in the last quarter. Bellevue Group AG increased its stake in Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after buying an additional 263,660 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Altimmune by 142.9% during the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after acquiring an additional 335,444 shares during the period. Exchange Traded Concepts LLC lifted its position in shares of Altimmune by 74.4% in the third quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock valued at $1,331,000 after acquiring an additional 92,498 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after purchasing an additional 4,772 shares in the last quarter. 78.05% of the stock is owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.